The arrival of 2024 has brought with it a complex web of challenges in the realm of reimbursement. The landscape has shifted dramatically, and the decline in reimbursements is a key concern for pharmacies across the nation.

The FDA responded to this request with an announcement on 8/25/23 that the effective date for full implementation of the DSCSA will be delayed for one year, becoming effective and enforceable on 11/27/24.

The United States Pharmacopeia (USP) Chapter <800> standards for hazardous drug handling will become effective and enforceable on November 1, 2023. This move coincides with the official implementation of the USP <795> and <797> standards for non-sterile and sterile compounding. USP <800> has been delayed from its original intended implementation date to align with corresponding references to the <795> and <797> chapters.

On November 1, 2023, the updated United States Pharmacopoeia (USP) chapters <795> and <797> compounding standards will become effective.  How well do you know what’s in the new standards and what this means for your pharmacy?  Let’s take a deep dive into this important topic for any pharmacy that engages in sterile or non-sterile compounding. 

This collaboration brings together the expertise of two industry leaders to streamline the process of meeting the regulatory requirements set forth by the DSCSA, ensuring enhanced patient safety and operational efficiency.

In brief, the prescription drug provisions of the Inflation Reduction Act aim to lower healthcare costs through several mechanisms.

Across the country, many states are reporting that scammers are targeting pharmacies, pretending to be Board of Pharmacy (BOP) inspectors, DEA agents, the FBI, or other false identities.

In April of 2021, a bill was introduced to the House of Representatives called the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021 (or simply, the BLOCKING Act).

Pharmacies assisting with the COVID-19 vaccination effort face evolving and…

Operation Warp Speed (OWS) is the coordinated effort between a number of federal agencies to accelerate the research, discovery, and production of a safe and effective vaccine for COVID-19.

In July during a virtual coffee chat with one of my pharmacy clients, we explored COVID-19 and its tremendous impact on stress levels within the nursing staff.

There’s no denying the fact that the COVID-19 pandemic has…

We recently published a blog post on USP Chapter <800>…

On October 24, 2018, the SUPPORT Act was signed into law, marking the single largest bill to combat the drug crisis in the history of the United States.

As more and more states address controlled substance abuse and the opioid crisis, Long-Term Care (LTC) pharmacies are feeling the urgency and need to be compliant with ever-increasing regulatory requirements.

With changes brought about by the CMS Final Rule and the impending changes being introduced with the new CMS case-mix classification model, the Patient-Driven Payment Model (PDPM), set to go into effect on October 1, 2019…